Brief: Paratek's Nuzyra Receives FDA Fast Track Designation For Treatment Of Pulmonary Nontuberculous Mycobacterial Disease
21/06/2022 21:28
June 21 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS’ NUZYRA® RECEIVES FDA FAST TRACK DESIGNATION FOR
THE
TREATMENT OF PULMONARY NONTUBERCULOUS MYCOBACTERIAL (NTM) DISEASE CAUSED BY
MYCOBACTERIUM AVIUM COMPLEX (MAC) AND MYCOBACTERIUM ABSCESSUS (MAB)
Source text for Eikon: ID:nGNX8YmKNq
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million